223 related articles for article (PubMed ID: 38648863)
1. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
[TBL] [Abstract][Full Text] [Related]
2. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
[TBL] [Abstract][Full Text] [Related]
3. ESHRE guideline: endometriosis.
Becker CM; Bokor A; Heikinheimo O; Horne A; Jansen F; Kiesel L; King K; Kvaskoff M; Nap A; Petersen K; Saridogan E; Tomassetti C; van Hanegem N; Vulliemoz N; Vermeulen N;
Hum Reprod Open; 2022; 2022(2):hoac009. PubMed ID: 35350465
[TBL] [Abstract][Full Text] [Related]
4. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based guideline: unexplained infertility†.
; Romualdi D; Ata B; Bhattacharya S; Bosch E; Costello M; Gersak K; Homburg R; Mincheva M; Norman RJ; Piltonen T; Dos Santos-Ribeiro S; Scicluna D; Somers S; Sunkara SK; Verhoeve HR; Le Clef N
Hum Reprod; 2023 Oct; 38(10):1881-1890. PubMed ID: 37599566
[TBL] [Abstract][Full Text] [Related]
6. Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials.
Griesinger G; Blockeel C; Pierzynski P; Tournaye H; Višňová H; Humberstone A; Terrill P; Pohl O; Garner E; Donnez J; Loumaye E
Hum Reprod; 2021 Mar; 36(4):1007-1020. PubMed ID: 33534895
[TBL] [Abstract][Full Text] [Related]
7. ESHRE guideline: ovarian stimulation for IVF/ICSI
Ovarian Stimulation TEGGO; Bosch E; Broer S; Griesinger G; Grynberg M; Humaidan P; Kolibianakis E; Kunicki M; La Marca A; Lainas G; Le Clef N; Massin N; Mastenbroek S; Polyzos N; Sunkara SK; Timeva T; Töyli M; Urbancsek J; Vermeulen N; Broekmans F
Hum Reprod Open; 2020; 2020(2):hoaa009. PubMed ID: 32395637
[TBL] [Abstract][Full Text] [Related]
8. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
11. Good practice recommendations on add-ons in reproductive medicine†.
; Lundin K; Bentzen JG; Bozdag G; Ebner T; Harper J; Le Clef N; Moffett A; Norcross S; Polyzos NP; Rautakallio-Hokkanen S; Sfontouris I; Sermon K; Vermeulen N; Pinborg A
Hum Reprod; 2023 Nov; 38(11):2062-2104. PubMed ID: 37747409
[TBL] [Abstract][Full Text] [Related]
12. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
[TBL] [Abstract][Full Text] [Related]
13. Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium.
Loreti S; Thiele K; De Brucker M; Olsen C; Centelles-Lodeiro J; Bourgain C; Waelput W; Tournaye H; Griesinger G; Raes J; Vieira-Silva S; Arck P; Blockeel C; Mackens S
Hum Reprod; 2024 Feb; 39(2):403-412. PubMed ID: 38110714
[TBL] [Abstract][Full Text] [Related]
14. ESHRE guideline: number of embryos to transfer during IVF/ICSI†.
; Alteri A; Arroyo G; Baccino G; Craciunas L; De Geyter C; Ebner T; Koleva M; Kordic K; Mcheik S; Mertes H; Pavicic Baldani D; Rodriguez-Wallberg KA; Rugescu I; Santos-Ribeiro S; Tilleman K; Woodward B; Vermeulen N; Veleva Z
Hum Reprod; 2024 Apr; 39(4):647-657. PubMed ID: 38364208
[TBL] [Abstract][Full Text] [Related]
15. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
17. Psychosocial wellbeing shortly after allocation to a freeze-all strategy compared with a fresh transfer strategy in women and men: a sub-study of a randomized controlled trial.
Pilegaard SP; Schmidt L; Stormlund S; Koert E; Bogstad JW; Prætorius L; Nielsen HS; la Cour Freiesleben N; Sopa N; Klajnbard A; Humaidan P; Bergh C; Englund ALM; Løssl K; Pinborg A
Hum Reprod; 2023 Nov; 38(11):2175-2186. PubMed ID: 37742131
[TBL] [Abstract][Full Text] [Related]
18. Endometriosis classification systems: an international survey to map current knowledge and uptake.
; Zondervan KT; Missmer S; Abrao MS; Einarsson JI; Horne AW; Johnson NP; Lee TTM; Petrozza J; Tomassetti C; Vermeulen N; Grimbizis G; De Wilde RL
Hum Reprod Open; 2022; 2022(1):hoac002. PubMed ID: 35237731
[TBL] [Abstract][Full Text] [Related]
19. Does luteal phase progesterone supplementation affect physical and psychosocial well-being among women undergoing modified natural cycle-FET? A sub-study of a randomized controlled trial.
Colombo C; Pistoljevic-Kristiansen N; Saupstad M; Bergenheim SJ; Spangmose AL; Klajnbard A; la Cour Freiesleben N; Løkkegaard EC; Englund AL; Husth M; Breth Knudsen U; Alsbjerg B; Prætorius L; Løssl K; Schmidt L; Pinborg A
Hum Reprod; 2023 Oct; 38(10):1970-1980. PubMed ID: 37634089
[TBL] [Abstract][Full Text] [Related]
20. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial.
Boudry L; Mateizel I; Wouters K; Papaleo E; Mackens S; De Vos M; Racca A; Adriaenssens T; Tournaye H; Blockeel C
Hum Reprod; 2024 Mar; 39(3):538-547. PubMed ID: 38199789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
